Boundless Bio, Inc. (0001782303) Files SEC Form 4 – Key Details Here
Boundless Bio, Inc. recently filed a Form 4 with the Securities and Exchange Commission (SEC), indicating changes in ownership of company securities by corporate insiders. Form 4 is required to be filed with the SEC whenever there are changes in ownership of company stock by directors, officers, or beneficial owners of more than 10% of the company’s stock. This filing is crucial for investors and analysts as it provides transparency regarding insider trading activities within the company.
Boundless Bio, Inc. is a biotechnology company focused on discovering and developing innovative cancer therapies. With a commitment to addressing unmet medical needs in oncology, the company leverages its expertise in cancer biology to advance novel treatment options for patients. For more information about Boundless Bio, Inc., please visit their official website here.
Overall, this Form 4 filing by Boundless Bio, Inc. offers valuable insights into the company’s insider trading activities. Investors and stakeholders can use this information to make informed decisions about their investment in the company and stay updated on changes in ownership among key individuals within Boundless Bio, Inc.
Read More:
Boundless Bio, Inc. (Issuer 0001782303) Submits Form 4 Filing to SEC
